Drug General Information
Drug ID	D02NMO
Former ID	DPR000047
Drug Name	FR-79620
Synonyms	3-(5-methyl-2-phenyl-1H-imidazol-4-yl)pyridine
Drug Type	Small molecular drug
Indication	Eating disorder; Obesity; Diabetes [ICD9: 250, 278, 307.5; ICD10:E08-E13, E66, F50]		Preclinical	[536122]
Company	Fujisawa
Structure		Download 2D MOL 3D MOL
Formula	C15H13N3
Canonical SMILES	CC1=C(N=C(N1)C2=CC=CC=C2)C3=CN=CC=C3
InChI	1S/C15H13N3/c1-11-14(13-8-5-9-16-10-13)18-15(17-11)12-6-3-2-4-7-12/h2-10H,1H3,(H,17,18)
InChIKey	CAQAIFUDUGDPFB-UHFFFAOYSA-N
PubChem Compound ID	10421577
PubChem Substance ID	15440049, 22764581, 42251630, 76474719, 103165099, 104005736, 136079467, 137024533, 142475519, 232996332
Target and Pathway
Target(s)	Neuropeptide Y receptor 5	Target Info	Antagonist	[536122]
KEGG Pathway	Neuroactive ligand-receptor interaction
Reactome	Peptide ligand-binding receptors
	G alpha (i) signalling events
WikiPathways	GPCRs, Class A Rhodopsin-like
	Peptide GPCRs
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 536122	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.
Ref 536122	Emerging drugs for obesity: linking novel biological mechanisms to pharmaceutical pipelines. Expert Opin Emerg Drugs. 2005 Aug;10(3):643-60.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.